Aura Biosciences, Inc. (AURA) Stock Price & Analysis
Aura Biosciences, Inc. (AURA) fell 2.08% to USD 7.05 as of July 26, 2026 at 10:22 UTC, according to Nexqual real-time market data.
AURA last closed at USD 7.2; the session ranged USD 6.99–7.23 on volume of 307,047 shares. Market capitalization is $729.23M, with a 52-week range of USD 4.73–9.54 (NGM). Source: Nexqual, July 26, 2026 at 10:22 UTC.
Key Statistics (as of July 26, 2026 at 10:22 UTC)
| Price | USD 7.05 |
|---|---|
| Change | ▼ 2.08% (down) |
| Previous Close | USD 7.2 |
| Open | USD 7.18 |
| Day Range | USD 6.99 – 7.23 |
| 52-Week Range | USD 4.73 – 9.54 |
| Volume | 307,047 shares |
| Market Cap | $729.23M |
| Exchange | NGM |
Technical Analysis (AURA)
Nexqual's technical model rates AURA "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 26, 2026 at 10:22 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 52.49 (neutral) |
| vs SMA50 | Above (USD 7.03) |
| MACD | 0.02 (positive) |
Analyst Ratings (AURA)
Wall Street analysts rate AURA "Strong Buy" based on 5 analysts, with a mean price target of USD 18.8 (range USD 15–24), per Nexqual as of July 26, 2026 at 10:22 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 18.8 |
| High Target | USD 24 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (AURA)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.5 vs est -0.4 ▼ miss |
| 2025-12-31 | USD -0.37 vs est -0.43 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -0.47 ▲ beat |
| 2025-06-30 | USD -0.47 vs est -0.48 ▲ beat |
Source: Nexqual, July 26, 2026 at 10:22 UTC.
Financials & Fundamentals (AURA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -95.57% |
| Debt / Equity | 15.84 |
| Current Ratio | 7.09 |
| Total Cash | $114.73M |
| Total Debt | $16.99M |
| Free Cash Flow | $-51.56M |
Source: Nexqual, July 26, 2026 at 10:22 UTC.
Financial Health Score (AURA)
Nexqual rates Aura Biosciences, Inc.'s overall financial health "Mixed" across five dimensions, as of July 26, 2026 at 10:22 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $115M cash vs $17M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$91M |
| Efficiency | Critical — ROE -96%, ROA -50.6% |
Ownership (AURA)
| Insider Ownership | +1.16% |
|---|---|
| Institutional Ownership | +49.39% |
| Shares Outstanding | 103.44M |
| Float | 93.30M |
| Short % of Float | +5.46% |
Source: Nexqual, July 26, 2026 at 10:22 UTC.
Leadership (AURA)
Aura Biosciences, Inc. is led by Natalie C. Holles (age 52), President, CEO & Director, per Nexqual as of July 26, 2026 at 10:22 UTC.
| President, CEO & Director | Natalie C. Holles (age 52) |
|---|---|
| Chief Financial & Business Officer | Anthony S. Gibney (age 54) |
| Chief Medical Officer & President of Research and Development | J. Jill Hopkins (age 60) |
Major Backers & Investors (AURA)
Notable institutional backers of Aura Biosciences, Inc. include Matrix Capital Management Company LP, Frazier Life Sciences Management, L.P. , Adage Capital Partners GP L.L.C., according to Nexqual as of July 26, 2026 at 10:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Matrix Capital Management Company LP | 6.7% |
| Frazier Life Sciences Management, L.P. | 4.93% |
| Adage Capital Partners GP L.L.C. | 4.72% |
| Long Focus Capital Management, LLC | 4.47% |
| Suvretta Capital Management, LLC | 4.23% |
| Medicxi Ventures Management (Jersey) Ltd | 2.94% |
| Nantahala Capital Management, LLC | 2.05% |
| Franklin Resources, Inc. | 2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.13% |
| Vanguard Group | 4.49% |
Source: Nexqual, July 26, 2026 at 10:22 UTC.
From Aura Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors.
- The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
- Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.
- It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | USD 5.85 | ▼ 4.88% |
| JBIO | Jade Biosciences, Inc. | USD 20.08 | ▲ 1.16% |
| TYRA | Tyra Biosciences, Inc. | USD 30.63 | ▲ 0.13% |
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
| CGEM | Cullinan Therapeutics, Inc. | USD 17.1 | ▼ 3.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 10:22 UTC. This page is informational and not investment advice.